Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders

Launched by GENESIS ATHENS CLINIC · Dec 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of a treatment called autologous platelet rich plasma (PRP) infused directly into the ovaries to see if it can help women who have a poor response to fertility treatments. Specifically, the goal is to improve how well their ovaries respond to medications that stimulate egg production, which is especially important for women undergoing a procedure called intracytoplasmic sperm injection (ICSI).

To participate in this trial, women must be aged between 40 and 45 and meet certain criteria indicating they have a poor ovarian response. This includes having low levels of a hormone called AMH or fewer than three eggs produced during standard treatment. Participants should not have any other serious reproductive health issues or conditions that could complicate their treatment. If eligible, women can expect to receive the PRP treatment as part of the study and will be closely monitored throughout the process. This trial is currently recruiting participants, and it aims to provide new insights into improving fertility for women facing challenges in becoming pregnant.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• Poor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following):
• • 1. Age ≥ 40 years
• • 2. AMH \< 1.1 ng/ml OR AFC \< 7
• • 3. ≤ 3 oocytes with a conventional stimulation protocol
• • Discontinuation of any complementary/adjuvant treatment including hormone replacement and acupuncture, for at least three months prior to recruitment.
• • Willing to comply with study requirements
• Exclusion Criteria:
• • Any pathological disorder related to reproductive system anatomy
• • Cycle irregularities
• • Amenorrhea
• • Endometriosis
• • Adenomyosis
• • Fibroids and adhesions
• • Infections in reproductive system
• • Current or previous diagnosis of cancer in reproductive system
• • History of familiar cancer in reproductive system
• • Severe male factor infertility
• • Prior referral for Preimplantation Genetic Testing (PGT) -Ovarian inaccessibility -Endocrinological disorders (Hypothalamus-
• • Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)
• • BMI\>30 kg/m2 or BMI\<18.5 kg/m2
• • Systematic autoimmune disorders